Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innova CaptabNSE:INNOVACAP -2.34%67 ROC (Joel Greenblatt) % is 19.82% as of Jun. 2026, which is 34% below its 10-year median of 30.12. GuruFocus rates NSE:INNOVACAP with a GF Score™ of 67/100 and a GF Value™ of ₹1,066.19 (Fairly Valued). The stock has 6 warning signs investors should review. Among 980 Drug Manufacturers companies, Innova Captab ranks better than 60% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Innova Captab's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 19.82%.
The historical rank and industry rank for Innova Captab's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:INNOVACAP'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 16.13 Med: 30.12 Max: 72.97
Current: 18.07
During the past 8 years, Innova Captab's highest ROC (Joel Greenblatt) % was 72.97%. The lowest was 16.13%. And the median was 30.12%.
NSE:INNOVACAP's ROC (Joel Greenblatt) % is ranked better than 60% of 980
companies
in the Drug Manufacturers industry
Industry Median: 11.685
vs NSE:INNOVACAP: 18.07
Innova Captab's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -16.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Innova Captab ROC (Joel Greenblatt) % Related Terms
Innova Captab ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Innova Captab's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INNOVACAP vs ZTS: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Innova Captab's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innova Captab ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Innova Captab's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Innova Captab's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 19.82% mean?
Innova Captab (NSE:INNOVACAP) has a ROC (Joel Greenblatt) % of 19.82% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innova Captab and its competitors. This is 34% below median its historical median of 30.12. Over the past decade, Innova Captab's ROC (Joel Greenblatt) % has ranged from 16.13 to 72.97. According to the industry distribution chart, Innova Captab ranks #392 out of 980 companies in the Drug Manufacturers industry, placing it in the top 40%.
Is Innova Captab's ROC (Joel Greenblatt) % too high?
Innova Captab's current ROC (Joel Greenblatt) % of 19.82% is 34% below median its 10-year median of 30.12. Over the past 10 years, this metric has ranged from a low of 16.13 to a high of 72.97. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.69. Innova Captab's value of 19.82% is 69.6% above this industry median. Based on the distribution chart, Innova Captab ranks #392 out of 980 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Innova Captab has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innova Captab's ROC (Joel Greenblatt) % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Innova Captab ranks #392 out of 980 companies for ROC (Joel Greenblatt) %. This puts Innova Captab in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.69. Innova Captab's value of 19.82% is 69.6% above this benchmark. Historically, Innova Captab's own ROC (Joel Greenblatt) % has ranged from 16.13 to 72.97 over the past decade. While the company's 10-year median is 30.12 vs. the industry median of 11.69, Innova Captab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.69, based on 980 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innova Captab's current ROC (Joel Greenblatt) % of 19.82% is 69.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Innova Captab and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innova Captab's current ROC (Joel Greenblatt) % is 19.82%, which is 34% below median its own 10-year median of 30.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innova Captab stock overvalued right now?
Based on GuruFocus' analysis, Innova Captab (NSE:INNOVACAP) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,066.19, compared to a current price of ₹1,063.05 — trading 0.3% below its estimated fair value. The current ROC (Joel Greenblatt) % is 19.82%, which is 34% below median its 10-year median of 30.12 and 69.6% above the Drug Manufacturers industry median of 11.69. Innova Captab's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Innova Captab (NSE:INNOVACAP), the current ROC (Joel Greenblatt) % is 19.82% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innova Captab (NSE:INNOVACAP) Overvalued in 2026?
Based on GuruFocus' analysis, Innova Captab stock appears to be undervalued.
The current stock price of ₹1,063.05 is trading 0.3% below its estimated GF Value™ of ₹1,066.19.
GuruFocus considers Innova Captab to be Fairly Valued.
Key valuation signals for NSE:INNOVACAP:
ROC (Joel Greenblatt) %: 19.82% (34% below median its 10-year median of 30.12)
GF Value™: ₹1,066.19 vs. price of ₹1,063.05 (0.3% below fair value)
Industry Position: 69.6% above the Drug Manufacturers median (#392 of 980)
No single metric tells the full story. See the NSE:INNOVACAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innova Captab Ltd is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company has identified "Drugs and pharmaceutical products" as single operating segment. The company has presence in India, and Outside India. The company generates majority of revenue from India. The company's products are Cephalosporins, Proton Pump Inhibitor, Antocholinergic and Heparin NSAIDs, Analgesics and Antipyretic, Anticold and Antiallergic, Antiemetic, Antidiabetic, Antispasmodic, Antifibrinolytic, Cardiovascular, Antioxidant and Vitamins, Antihyperuricemia and Antigout, Fluoroquinolone and Macrolide, Nootropics and Neurotonics/ Neurotrophics, Antiulcerative, Antimalarial Anxiolytic, Anticonvulsant and Antipsychotic, Bladder and Prostate Disorder, etc.
67GF Score
Get the complete analysis for NSE:INNOVACAP
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INNOVACAP has been successfully added to your 
